Novo Nordisk Expand Use of APAS Independence

Key points

• Novo Nordisk orders two additional APAS Independence instruments
• Purchase includes development of custom laboratory interface software
• Follows successful evaluation over the past 12 months

Full summary

Clever Culture Systems Ltd (ASX: CC5) announced that Novo Nordisk has placed an order for two additional APAS Independence instruments, increasing its total to three. The order includes the development of a custom laboratory interface software to integrate with Novo Nordisk's global Laboratory Information Management System (LIMS). This follows a successful evaluation of the APAS technology over the past 12 months, with positive results presented at the APAS Expert User Group meeting. The new instruments will be installed in Denmark to complete a formal global validation of the technology, which is a prerequisite for potential broader deployment. The company expects a step-change increase in sales starting from FY27, driven by expansion with existing customers and new opportunities.

Guidance

CCS expects a step-change increase in sales starting FY27.

Outlook

The company anticipates that expansion from existing customers will drive significant sales growth from FY27 and beyond.